help button home button Am J Pathol International Conference on Pathology of Chest Diseases
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Order Full text via Infotrieve
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Niculescu, F.
Right arrow Articles by Vlaicu, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Niculescu, F.
Right arrow Articles by Vlaicu, R.

American Journal of Pathology, Vol 140, 1039-1043, Copyright © 1992 by American Society for Investigative Pathology

REGULAR ARTICLES

Persistent complement activation on tumor cells in breast cancer

F Niculescu, HG Rus, M Retegan and R Vlaicu
Medical Clinic No. 1, Cluj-Napoca, Romania.

The neoantigens of the C5b-9 complement complex, IgG, C3, C4, S- protein/vitronectin, fibronectin, and macrophages were localized on 17 samples of breast cancer and on 6 samples of benign breast tumors using polyclonal or monoclonal antibodies and the streptavidin-biotin- peroxidase technique. All the tissue samples with carcinoma in each the TNM stages presented C5b-9 deposits on the membranes of tumor cells, thin granules on cell remnants, and diffuse deposits in the necrotic areas. When chemotherapy and radiation therapy preceded surgery, C5b-9 deposits were more intense and extended. The C5b-9 deposits were absent in all the samples with benign lesions. S-protein/vitronectin was present as fibrillar deposits in the connective tissue matrix and as diffuse deposits around the tumor cells, less intense and extended than fibronectin. IgG, C3, and C4 deposits were present only in carcinoma samples. The presence of C5b-9 deposits is indicative of complement activation and its subsequent pathogenetic effects in breast cancer.


This article has been cited by other articles:


Home page
 EndocrinologyHome page
B. G. Hollier, J. A. Kricker, D. R. Van Lonkhuyzen, D. I. Leavesley, and Z. Upton
Substrate-Bound Insulin-Like Growth Factor (IGF)-I-IGF Binding Protein-Vitronectin-Stimulated Breast Cell Migration Is Enhanced by Coactivation of the Phosphatidylinositide 3-Kinase/AKT Pathway by {alpha}v-Integrins and the IGF-I Receptor
Endocrinology, March 1, 2008; 149(3): 1075 - 1090.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Imai, R. Ohta, J. C. Varela, H. Song, and S. Tomlinson
Enhancement of Antibody-Dependent Mechanisms of Tumor Cell Lysis by a Targeted Activator of Complement
Cancer Res., October 1, 2007; 67(19): 9535 - 9541.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. M. Donev, D. S. Cole, B. Sivasankar, T. R. Hughes, and B. P. Morgan
p53 Regulates Cellular Resistance to Complement Lysis through Enhanced Expression of CD59
Cancer Res., February 15, 2006; 66(4): 2451 - 2458.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pathol.Home page
T Inoue, M Yamakawa, and T Takahashi
Expression of complement regulating factors in gastric cancer cells
Mol. Pathol., June 1, 2002; 55(3): 193 - 199.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. A. Caragine, N. Okada, A. B. Frey, and S. Tomlinson
A Tumor-expressed Inhibitor of the Early but not Late Complement Lytic Pathway Enhances Tumor Growth in a Rat Model of Human Breast Cancer
Cancer Res., February 1, 2002; 62(4): 1110 - 1115.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1992 by the American Society for Investigative Pathology.